Spanish pharmaceutical company Grifols SA (GRF.MC) Tuesday said its U.S. unit, Grifols Inc., is selling around $600 million in long-term bonds in a private placement.

The Barcelona-based producer of hemoderivatives said the bonds have maturities of seven, 10 and 12 years, in a regulatory filing. It didn't provide any further details.

Company Web site: www.grifols.com

-By Ana Garcia, EFE-Dow Jones; +34 913958120; ana.garcia@dowjones.com